We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Receives Milestone Payment as part of its Discovery Alliance with Boehringer Ingelheim
News

Evotec Receives Milestone Payment as part of its Discovery Alliance with Boehringer Ingelheim

Evotec Receives Milestone Payment as part of its Discovery Alliance with Boehringer Ingelheim
News

Evotec Receives Milestone Payment as part of its Discovery Alliance with Boehringer Ingelheim

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Receives Milestone Payment as part of its Discovery Alliance with Boehringer Ingelheim"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG has announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of € 1.0 m to Evotec.

The milestone was for the transition of a back-up compound from a respiratory programme into pre-clinical development.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We have now achieved twenty three milestones as part of the collaboration with Boehringer Ingelheim. The completed research phase of this alliance has led to significant potential clinical milestones and royalties for compounds that are already in pre-clinical and clinical development if they progress successfully.”

Advertisement